Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA)’s stock price has plunge by 2.22relation to previous closing price of 18.01. Nevertheless, the company has seen a 1.83% surge in its stock price over the last five trading sessions. zacks.com reported 2024-09-13 that Teva’s reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
TEVA has 36-month beta value of 0.89. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 17 as “hold,” and 5 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TEVA is 1.13B, and currently, short sellers hold a 2.11% ratio of that float. The average trading volume of TEVA on September 16, 2024 was 8.90M shares.
TEVA’s Market Performance
The stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen a 1.83% increase in the past week, with a 2.22% rise in the past month, and a 5.80% gain in the past quarter. The volatility ratio for the week is 3.22%, and the volatility levels for the past 30 days are at 2.43% for TEVA. The simple moving average for the last 20 days is 0.32% for TEVA stock, with a simple moving average of 27.49% for the last 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the current year.
TEVA Trading at 5.37% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.51% of loss for the given period.
Volatility was left at 2.43%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares surge +0.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.45% upper at present.
During the last 5 trading sessions, TEVA rose by +1.83%, which changed the moving average for the period of 200-days by +86.34% in comparison to the 20-day moving average, which settled at $18.36. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 76.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 98,943 shares at the price of $17.30 back on Aug 12 ’24. After this action, Daniell Richard now owns 0 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,711,447 using the latest closing price.
Grant Angus, the EVP, Business Development of Teva- Pharmaceutical Industries Ltd. ADR, sale 4,065 shares at $17.28 during a trade that took place back on Aug 09 ’24, which means that Grant Angus is holding 8,848 shares at $70,243 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.5 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.03. The total capital return value is set at 0.09. Equity return is now at value -6.61, with -1.05 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 2.93. The interest coverage ratio of the stock is 2.57.
Currently, EBITDA for the company is 4.27 billion with net debt to EBITDA at 3.71. When we switch over and look at the enterprise to sales, we see a ratio of 2.3. The receivables turnover for the company is 4.33for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
To put it simply, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has had a better performance in recent times. Analysts have a bearish opinion on the stock, with some rating it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
